Skip to search formSkip to main contentSkip to account menu

Anti-CD70 Monoclonal Antibody ARGX-110

Known as: ARGX-110 
A defucosylated, humanized IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential… 
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
A pilot, phase Ib feasibility study of ARGX-110 in patients with nasopharyngeal carcinoma (NPC)
2016
2016
A phase I study in T cell lymphoma patients treated with anti-CD70 simple antibody (TM) ARGX-110
2014
2014
A phase I, first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies.
3023 Background: Distribution of CD70, a TNF superfamily receptor involved in transient, rapid-onset immune response, is normally… 
2013
2013
Abstract 5470: Pre-clinical characterization of ARGX-110: A neutralizing, humanized monoclonal antibody to the human CD70 antigen with enhanced ADCC properties.
The expression of CD70 is normally restricted to activated B- and T- cells, as well as mature dendritic cells. Overexpression has… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)